Indoleamine 2,3-dioxygenase, a new prognostic marker in sentinel lymph nodes of melanoma patients

European Journal of Cancer

Volumn 48, Issue 13, 2012, Pages 2004-2011

  Speeckaert, Reinhart ^a   Vermaelen, Karim ^a   Van Geel, Nanja ^a   Autier, Philippe ^b   Lambert, Jo ^a   Haspeslagh, Marc ^a   Van Gele, Mireille ^a   Thielemans, Kris ^c   Neyns, Bart ^d   Roche, Nathalie ^a   Verbeke, Natacha ^a   Deron, Philippe ^a   Speeckaert, Marijn ^a   Brochez, Lieve ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b INTERNATIONAL PREVENTION RESEARCH INSTITUTE   (France)

^c FACULTY OF MEDICINE AND PHARMACY   (Belgium)

^d UZ Brussel ^*  (Belgium)

Author keywords

Indoleamine 2,3 dioxygenase; Melanoma; Prognosis; Regulatory T cell; Sentinel node

Indexed keywords

CD28 ANTIGEN; CD3 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAMMA INTERFERON; INDOLEAMINE 2,3 DIOXYGENASE; TRANSCRIPTION FACTOR FOXP3;

ADULT; ARTICLE; CANCER INVASION; CANCER PROGNOSIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DISEASE MARKER; FEMALE; FLOW CYTOMETRY; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOSTIMULATION; MAJOR CLINICAL STUDY; MALE; MELANOMA; OVERALL SURVIVAL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SENTINEL LYMPH NODE; SURVIVAL RATE;

ADULT; CTLA-4 ANTIGEN; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; INTERFERON-GAMMA; LEUKOCYTES, MONONUCLEAR; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MELANOMA; MIDDLE AGED; PROGNOSIS; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS; T-LYMPHOCYTES, REGULATORY;

EID: 84865118647     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2011.09.007     Document Type: Article

References (28)

1. T. Okamato, S. Toné, and H. Kanouchi Transcriptional regulation of indoleamine 2,3-dioxygenase (IDO) by tryptophan and its analogue: down-regulation of the indoleamine 2,3-dioxygenase (IDO) transcription by tryptophan and its analogue Cytotechnology 5 2007 107 113 (Pubitemid 47174823)
2. D.H. Munn, M. Zhou, and J.T. Attwood Prevention of allogeneic fetal rejection by tryptophan catabolism Science 281 1998 1191 1193 (Pubitemid 28406294)
3. G.K. Lee, H.J. Park, and M. Macleod Tryptophan deprivation densitizes activated T cells to apoptosis prior to cell division Immunology 107 2002 452 460 (Pubitemid 36693650)
4. A.L. Mellor, and D.H. Munn Tryptophan catabolism and T-cell tolerance: immunosuppression by starvation? Immunol Today 20 1999 469 473 (Pubitemid 29476077)
5. G. Frumento, R. Rotondo, and M. Tonetti Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase J Exp Med 196 2002 459 468
6. C. Uyttenhove, L. Pilotte, and I. Théate Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3 dioxygenase Nat Med 9 2003 1269 1274 (Pubitemid 37279849)
7. D.H. Munn, M.D. Sharma, and D. Hou Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes J Clin Invest 114 2004 280 290 (Pubitemid 39071633)
8. J.R. Lee, R.R. Dalton, and J.L. Messina Pattern of recruitment of immunoregulatory antigen-presenting cells in malignant melanoma Lab Invest 83 2003 1457 1466 (Pubitemid 37267829)
9. J.R. Brody, C.L. Costantino, and A.C. Berger Expression of indoleamine 2, 3-dioxygenase in metastatic malignant melanoma recruits regulatory T cells to avoid immune detection and affects survival Cell Cycle 8 2009 1930 1934
10. G. Gerlini, P. Di Gennaro, and G. Mariotti Indoleamine 2,3-dioxygenase+ cells correspond to the BDCA2+ plasmacytoid dendritic cells in human melanoma sentinel nodes J Invest Dermatol 130 2010 898 901
11. G. Weinlich, C. Murr, and L. Richardsen Decreased serum tryptophan concentration predicts poor prognosis in malignant melanoma patients Dermatology 214 2007 8 14 (Pubitemid 46032994)
12. S. Löb, A. Köningsrainer, and H.G. Rammensee Inhibitors of indoleamine-2,3-dioxygenase for cancer therapy: can we see the wood for the trees? Nat Rev Cancer 9 2009 445 452
13. G.C. Prendergast, R. Metz, and A.J. Muller IDO recruits Tregs in melanoma Cell Cycle 8 2009 1818 1819
14. J. Shimizu, S. Yamazaki, and S. Sakaghuchi Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity J Immunol 163 1999 5211 5218
15. M. Viguier, F. Lemaître, and O. Verola Foxp3 expressing CD4+CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells J Immunol 173 2004 1444 1453 (Pubitemid 38924326)
16. A. Ladányi, A. Mohos, and B. Somlai Foxp3(+) cell density in primary tumor has no prognostic impact in patients with cutaneous malignant melanoma Pathol Oncol Res 16 2010 303 309
17. P.A. Gimotty, and D. Guerry Prognostication in thin cutaneous melanomas Arch Pathol Lab Med 134 2010 1758 1763
18. F. Fallarino, C. Vacca, and C. Orabona Functional expression of indoleamine 2,3-dioxygenase by murine CD8α+ dendritic cells Int Immunol 14 2002 65 68 (Pubitemid 34083398)
19. A. Curti, S. Pandolfi, and B. Valzasina Modulation of tryptophan catabolism by human leukemic cells results in the conversion of CD25- into CD25+ T regulatory cells Blood 109 2007 2871 2877 (Pubitemid 46482083)
20. M.D. Sharma, D.Y. Hou, and Y. Liu Indoleamine 2,3-dioxygenase controls conversion of Foxp3+ Tregs to Th17-like cells in tumor-draining lymph nodes Blood 113 2009 6102 6111
21. B. Baban, A.M. Hansen, and P.R. Chandler A minor population of splenic dendritic cells expressing CD19 mediates IDO-dependent T cell suppression via type I IFN signaling following B7 ligation Int Immunol 17 2005 909 919 (Pubitemid 41417958)
22. R.B. Sørensen, S.R. Hadrup, and I.M. Svane Indoleamine 2,3 dioxygenase specific, cytotoxic T cells as immune regulators Blood 117 2011 2200 2210
23. T. Onodera, M.H. Jang, and Z. Guo Constitutive expression of IDO by dendritic cells of mesenteric lymph nodes: functional involvement of the CTLA-4/B7 and CCL22/CCR4 interactions J Immunol 183 2009 5608 5614
24. F.S. Hodi, S.J. O'Day, and D.F. McDermott Improved survival with ipilimumab in patients with metastatic melanoma N Eng J Med 363 2010 711 723
25. A. Hryniewicz, A. Boasso, and Y. Edghill-Smith CTLA-4 blockade decreases TGF-beta, IDO, and viral RNA expression in tissues of SIVmac251-infected macaques Blood 108 2006 3834 3842 (Pubitemid 44864566)
26. A. Raitala, M. Pertovaara, and Karjalainen Association of interferon-gamma +874(T/A) single nucleotide polymorphism with the rate of tryptophan catabolism in healthy individuals Scand J Immunol 61 2005 387 390 (Pubitemid 40637846)
27. J.H. Bream, A. Ping, and X. Zhang A single nucleotide polymorphism in the proximal IFN-gamma promoter alters control of gene transcription Genes Immun 3 2002 165 169 (Pubitemid 38961127)
28. U.F. Rohrig, L. Awad, and A. Grosdidier Rational design of indoleamine 2,3-dioxygenase inhibitors J Med Chem 53 2010 1172 1189